Clinical Trial Detail

NCT ID NCT02655822
Title Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Corvus Pharmaceuticals, Inc.
Indications

triple-receptor negative breast cancer

non-small cell lung carcinoma

melanoma

kidney cancer

colorectal cancer

prostate cancer

urinary bladder cancer

head and neck cancer

Therapies

Atezolizumab

CPI-444

Age Groups: adult

Additional content available in CKB BOOST